(Q31107603)

12 August 2017

1 reference

title

Proliferative diabetic retinopathy: predictive and preventive measures at hypoxia induced retinal changes (English)

1 reference

proliferative diabetic retinopathy

12 August 2017

1 reference

1 reference

Tatjana Josifova

1

1 reference

12 August 2017

Ivna Plestina-Borjan

series ordinal

2

1 reference

12 August 2017

Paul Bernhard Henrich

series ordinal

3

1 reference

12 August 2017

language of work or name

1 reference

1 March 2010

1 reference

12 August 2017

1 reference

12 August 2017

1

1 reference

12 August 2017

1

1 reference

12 August 2017

73-77

1 reference

Expression of Robo4 in the fibrovascular membranes from patients with proliferative diabetic retinopathy and its role in RF/6A and RPE cells.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

SPARC is a major secretory gene expressed and involved in the development of proliferative diabetic retinopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Long-term review of driving potential following bilateral panretinal photocoagulation for proliferative diabetic retinopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Expression of integrins in human proliferative diabetic retinopathy membranes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Rosiglitazone and delayed onset of proliferative diabetic retinopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Management of proliferative diabetic retinopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Proliferative diabetic retinopathy-The influence of diabetes control on the activation of the intraocular molecule system

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13167-010-0003-8

Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13167-010-0003-8

Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13167-010-0003-8

Insulin may cause deterioration of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13167-010-0003-8

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13167-010-0003-8

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13167-010-0003-8

Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13167-010-0003-8

Morphologic changes in the anterior segment after phacovitrectomy for proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13167-010-0003-8

Differences of ocular circulation in eyes with proliferative diabetic retinopathy after panretinal photocoagulation with and without rubeosis iridis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405300

Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy

25 November 2018

1 reference

12 December 2020

Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy

1 reference

12 December 2020

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

1 reference

12 December 2020

Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin)

1 reference

12 December 2020

10.1007/S13167-010-0003-8

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference

12 August 2017

PubMed publication ID

23199042

1 reference